Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo Patients

Inclusion Criteria: * Patients with clinical diagnosis of pure impetigo, impetigo contagiosa, or uncomplicated blistering impetigo * Patients 2 years of age or older, and in general good health * Patients with no less than two lesions and no more than seven lesions, area 0.5x0.5cm. * No known medical conditions that, in the Investigator's opinion could interfere with study participation * Patient / Patient's guardian (in the case of children) willing and able to comply with all requirement of the protocol * Patient / Patient's guardian willing and able to give written informed consent prior to participation in the study Exclusion Criteria: * Presence of skin diseases at or near the investigational area * Immunosuppressed state or other serious systemic disease * Signs and/or symptoms of systemic infection * Presence of skin infection/disorder not amenable to topical antibacterial treatment only * Presence of secondarily-infected animal/human bite * Presence of secondarily infected burn wound * Topical or systemic use of medicinal or other products before or during the study (oral or topical antibiotics, oral or topical corticosteroids and immuno modulators); or other drugs, which in the Investigators opinion could confound the evaluation of the effect of the study drugs * Known or suspected hypersensitivity to Minocycline or any of the excipients in the study medication * Participation in any other investigational drug study or use of (an) investigational drug(s) within the 30 days or 5 half-lives (whichever is longer) prior to randomization * Patients previously enrolled/randomized in this study * Use of another investigational drug within 30 days prior to entry into this study. * Pregnant or lactating women.